EpCAM-targeted near-infrared photoimmunotherapy (NIR-PIT) for the treatment of breast cancer.

ABSTRACT:

Background

Near-infrared photoimmunotherapy (NIR-PIT) is a targeted cancer treatment that uses antibody-IR700 conjugates and selectively destroys cancer cells expressing a target antigen when exposed to near-infrared (NIR) light. NIR-PIT not only destroys targeted cancer cells but also induces anticancer immune activation. Currently, epidermal growth factor receptor (EGFR) is the only clinically approved target for NIR-PIT. To expand the therapeutic potential of this therapy, we investigated EpCAM as a potential target for NIR-PIT.

Method

We first evaluated the target cell-killing efficacy of EpCAM-targeted NIR-PIT (EpCAM-NIR-PIT) using the antibody Edrecolomab in human breast and colon cancer models characterized by high EpCAM expression. Next, we evaluated anticancer immun

SUBMITTER: Furusawa A 

PROVIDER: S-EPMC12344674 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature